Keyphrases
Randomized Controlled Trial
100%
Estradiol
100%
Transgender
100%
Gender-affirming Hormone Therapy
72%
17-estradiol
45%
Treatment Effect
18%
Spironolactone
18%
Antiandrogen
18%
Sublingual
18%
Testosterone Suppression
18%
Dyslipidemia
9%
Insulin Sensitivity
9%
Tertiary Care Hospital
9%
Adverse Events
9%
Twice Daily
9%
Liver Disease
9%
Standard of Care
9%
Lipoproteins
9%
Cigarette Smoking
9%
Postmenopausal Women
9%
Route of Administration
9%
Cardiometabolic Disease
9%
Clinical Experience
9%
Coagulation Factors
9%
Randomized Clinical Trial
9%
Coagulopathy
9%
Transdermal
9%
Treatment-naïve
9%
Gonadotropin-releasing Hormone
9%
Testosterone
9%
Once-daily
9%
Gaps in Knowledge
9%
Current Guidelines
9%
Von Willebrand Factor
9%
Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
9%
Background Current
9%
Coagulation Factor XI
9%
Metabolic Factors
9%
Best Available Evidence
9%
Coagulation Factor IX
9%
Total Testosterone
9%
Lipid Panel
9%
Coagulation Factor II
9%
Gender Diverse People
9%
World Professional Association for Transgender Health
9%
Activated Protein C Resistance
9%
Glucose Sensitivity
9%
Pharmacology, Toxicology and Pharmaceutical Science
Randomized Controlled Trial
100%
Diethylstilbestrol
100%
Endocrine Therapy
80%
Spironolactone
20%
Blood Clotting Factor
20%
Antiandrogen
20%
Insulin Resistance
10%
Dyslipidemia
10%
Adverse Event
10%
Liver Disease
10%
Lipoprotein
10%
Protein C
10%
Cigarette Smoking
10%
Randomized Clinical Trial
10%
Transdermal
10%
Blood Clotting Disorder
10%
Route of Administration
10%
Von Willebrand Factor
10%
Blood Clotting Factor 11
10%
Prothrombin
10%
Blood Clotting Factor 9
10%
Gonadorelin Agonist
10%
Protein S
10%
Activated Protein C Resistance
10%